+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1654 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.

Age: 18Years +All GendersPhase Not Applicable
45 locations
I

Actively Recruiting

Healthy Volunteer

This research aims to evaluate whether creating dedicated HIV teams in hospitals across ten European countries can increase HIV testing rates among patients showing signs of HIV-related conditions. The study uses a stepped-wedge design, where hospitals switch from routine care to the new intervention in sequence. This approach compares outcomes before and after the teams are in place, helping to understand the impact of the intervention across various locations and medical specialties. The intervention involves establishing local HIV teams led by specialists and supported by nurses and data experts. These teams identify patients needing HIV tests through electronic health records, provide feedback to doctors to encourage testing, offer education to healthcare staff about HIV, reduce stigma, and improve connections to prevention and care services. This program integrates smoothly into regular hospital routines and aims to close gaps in HIV diagnosis. Participants HIV testing rates will be monitored by reviewing records before and after the intervention. Researchers will also assess new HIV diagnoses, changes in testing patterns by country and specialty, and healthcare professionals knowledge and attitudes toward HIV. The study includes ongoing evaluation of how well the teams operate, resource use, and cost-effectiveness. Data collection extends up to several years to observe long-term effects, with continuous monitoring of care access and prevention services.

Age: 18Years +All GendersPhase Not Applicable
28 locations
E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.

Age: 18Years +All Genders
22 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
O

Actively Recruiting

Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.

Age: 18Years +All GendersPhase 1Phase 2
23 locations
E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations

1-10 of 1,654

1